Status
Active, not recruiting
Phase
Not applicable
Enrollment
1,806
Locations
1
Results
Not posted
Publications
0
Study summary
This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in participants with SBS. SBS participants treated and not treated with teduglutide will be enrolled.
Interventions
No intervention details reported.
Timeline
First posted
Nov 21, 2013
Study start
Jun 23, 2014
Primary completion
Jun 30, 2032
Study completion
Jun 30, 2032
Results posted
Not reported
Registry updated
Oct 10, 2025
Outcomes
Occurrence of Colorectal Cancer in Short Bowel Syndrome (SBS) Participants With a Remnant Colon Currently Being Treated With or Ever Having Been Treated With Teduglutide
Time frame · 10 years
Incidence rates of colorectal cancer in participants will be calculated by dividing the number of incident colorectal cancer cases by the total number of person-years observed since beginning treatment with teduglutide.
Occurrence of Other Malignancy
Time frame · 10 years
Incidence rates of other malignancies will be calculated by dividing the number of incident cases by the total number of person-years observed since beginning treatment with teduglutide.
Occurrence of Benign Neoplasia of the Gastrointestinal (GI) tract, Hepatobiliary System, and Pancreas in Participants
Time frame · 10 years
Incidence rates of benign neoplasia of the GI tract, hepatobiliary system, and pancreas will be calculated by dividing the number of incident cases by the total number of person-years observed since beginning treatment with teduglutide.
Occurrence of Colorectal Polyps
Time frame · 10 years
Incidence rates of colorectal polyps will be calculated by dividing the number of incident cases by the total number of person-years observed since beginning treatment with teduglutide.
Occurrence of Intestinal Obstruction
Time frame · 10 years
Incidence rates of intestinal obstruction will be calculated by dividing the number of incident cases by the total number of person-years observed since beginning treatment with teduglutide.
Occurrence of Pancreatic and Biliary Disease
Time frame · 10 years
Incidence rates of pancreatic and biliary disease will be calculated by dividing the number of incident cases by the total number of person-years observed since beginning treatment with teduglutide.
Occurrence of Heart Failure and Other Manifestations of Volume Overload
Time frame · 10 years
Incidence rates of heart failure and other manifestations of volume overload will be calculated by dividing the number of incident cases by the total number of person-years observed since beginning treatment with teduglutide.
Occurrence of Allergic/Hypersensitivity Reaction to Teduglutide
Time frame · 10 years
Incidence rates of allergic/hypersensitivity reactions to teduglutide will be calculated by dividing the number of incident cases by the total number of person-years observed since beginning treatment with teduglutide.
Occurrence of Other Adverse Events (AEs) Potentially Related to Treatment with Teduglutide
Time frame · 10 years
Incidence rates of other AEs will be calculated by dividing the number of incident cases by the total number of person-years observed since beginning treatment with teduglutide. Incidence rates of other AEs will be calculated by dividing the number of incident cases by the total number of person-years observed since beginning treatment with teduglutide. An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product (ICH Guidance E2A 1995). This includes an exacerbation of a pre-existing condition.
Actual Volume Change in Parenteral Support (PS)
Time frame · 10 years
PS will be measured by parenteral treatment volume (liters/week) and days (days/week) that occurred in the 7 days prior to the visit.
Percentage Volume Change in Parenteral Support (PS)
Time frame · 10 years
PS will be measured by parenteral treatment volume (liters/week) and days (days/week) that occurred in the 7 days prior to the visit.
Eligibility
Inclusion Criteria: 1. Male and female participants, of any age, with a diagnosis of short bowel syndrome (SBS). 2. Signed informed consent and medical records release by the participant or a legally acceptable representative 3. Participants who have never received teduglutide treatment must be on parenteral nutrition (PN)/intravenous (IV) fluids support for at least 6 months at the time of enrollment. Exclusion criteria: 1. Participants currently participating in a blinded clinical trial or their extension studies. 2. Participants who have never been on PN/IV support. 3. Participants who are currently or previously exposed to any Glucagon-like peptide 2 (GLP-2) analogs other than teduglutide.
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
Shire
Lexington, Massachusetts, United States
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Takeda · Short Bowel Syndrome
Phase 3
Recruiting
13
2026-06
International Centre for Diarrhoeal Disease Research, Bangladesh · Environmental Enteric Dysfunction
Phase 2
Not yet recruiting
55
2026-04
Takeda · Short Bowel Syndrome
Not applicable
Active, not recruiting
250
2026-04
Takeda · Short Bowel Syndrome (SBS)
Not applicable
Recruiting
12
2026-03
Meyer Children's Hospital IRCCS · Short Bowel Syndrome (SBS)
Not applicable
Recruiting
50
2026-02
Takeda · Short Bowel Syndrome (SBS)
Not applicable
Recruiting
600
2026-01
Assistance Publique - Hôpitaux de Paris · Short Bowel Syndrome
Phase 4
Completed
25
2025-09
Takeda · Short Bowel Syndrome (SBS)
Not applicable
Completed
52
2025-04
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.